Cork-based medical technology company NeuroBell has successfully secured $5.5 million (€4.8 million) in a new investment round to accelerate the United States launch of its LUNA neonatal brain monitor. The funding round was led by Elkstone and saw participation from major existing investors alongside Parkview Health, a prominent US health system operating 15 hospitals. This strategic financial backing coincides with NeuroBell establishing a new office in Fort Wayne, Indiana, to directly anchor its American market expansion.
The company, which spun out from University College Cork in 2023 following nearly a decade of academic research, designed the LUNA device to address a critical gap in newborn care. Neonatal seizures are notoriously difficult to detect because they frequently display no outward physical symptoms. However, delays in identifying these silent episodes can significantly compound the risk of long-term pediatric brain damage, making rapid diagnosis a matter of vital urgency.
Related: Wearable neurotech company NeuroLife launches with $2.9M to restore movement after stroke
LUNA offers a stark departure from bulky, traditional hospital equipment by delivering a pocket-sized, wireless electroencephalogram (EEG) device tailored specifically for modern Neonatal Intensive Care Units (NICUs). It leverages embedded artificial intelligence to provide bedside clinical teams with automated seizure analysis and remote viewing capabilities. The device has already proven its efficacy in a 2025 clinical investigation at Cork University Maternity Hospital, where it demonstrated high diagnostic accuracy and a substantial reduction in false alarms compared to legacy systems.
With this fresh influx of capital, NeuroBell is finalizing its regulatory push for US Food and Drug Administration (FDA) clearance, which is anticipated in the coming months. The partnership with Parkview Health is expected to serve as a vital pipeline for clinical adoption and market access once clearance is granted.
“LUNA exists to put clinical-grade brain monitoring in the hands of every NICU team, wherever they are,” Dr Mark O’Sullivan, CEO of NeuroBell, said. “This investment gives us the resources to scale that vision to patients in the US and across Europe.”
